Abstract
The Structural Vaccinology (SV) approach is the logical evolution of Reverse Vaccinology: a genome-based approach combined with structural biology, with the idea that protective determinants can be used to selectively engineer the antigens that can be re-designed and simplified for inclusion in vaccine combinations. The final objectives of the rational structure-based antigen optimization are the facilitation of industrial-scale production of the antigens combination, obtain a greater immunogenicity and a greater safety profile and finally expand the breadth of protection. Structural Vaccinology is particularly powerful in case of antigenic variation between closely related strains and species. Several examples are available in literature of how SV has already been applied successfully to several bacterial and viral projects. The examples of structure-based antigens optimization reviewed here describe different template procedures that can be followed to develop improved vaccines against other pathogens and potentially help resolve challenges in manufacturing or efficacy.
Keywords: Vaccines, X-ray crystallography, TEM Group B streptococcus, Meningococcus B, structure-based vaccines, Ehrlichia chaffeensis, OspA, alpha-hemolysin, HIV vaccines, influenza hemagglutinin.
Current Topics in Medicinal Chemistry
Title:Structural Vaccinology: A Three-dimensional View for Vaccine Development
Volume: 13 Issue: 20
Author(s): Ilaria Ferlenghi, Roberta Cozzi and Maria Scarselli
Affiliation:
Keywords: Vaccines, X-ray crystallography, TEM Group B streptococcus, Meningococcus B, structure-based vaccines, Ehrlichia chaffeensis, OspA, alpha-hemolysin, HIV vaccines, influenza hemagglutinin.
Abstract: The Structural Vaccinology (SV) approach is the logical evolution of Reverse Vaccinology: a genome-based approach combined with structural biology, with the idea that protective determinants can be used to selectively engineer the antigens that can be re-designed and simplified for inclusion in vaccine combinations. The final objectives of the rational structure-based antigen optimization are the facilitation of industrial-scale production of the antigens combination, obtain a greater immunogenicity and a greater safety profile and finally expand the breadth of protection. Structural Vaccinology is particularly powerful in case of antigenic variation between closely related strains and species. Several examples are available in literature of how SV has already been applied successfully to several bacterial and viral projects. The examples of structure-based antigens optimization reviewed here describe different template procedures that can be followed to develop improved vaccines against other pathogens and potentially help resolve challenges in manufacturing or efficacy.
Export Options
About this article
Cite this article as:
Ferlenghi Ilaria, Cozzi Roberta and Scarselli Maria, Structural Vaccinology: A Three-dimensional View for Vaccine Development, Current Topics in Medicinal Chemistry 2013; 13 (20) . https://dx.doi.org/10.2174/15680266113136660187
DOI https://dx.doi.org/10.2174/15680266113136660187 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology Cerebral Palsy: Classification, Etiology and Evolution of Spine Deformity in Children and Adolescents
Current Pediatric Reviews The Yin and Yang of Antiviral Innate Immunity in Central Nervous System
Current Pharmaceutical Design Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting
Current Molecular Medicine The Role of Bacterial Lipopolysaccharides as Immune Modulator in Vaccine and Drug Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Evidence on the Evaluation and Management of Fever Without a Source in Infants Aged 0-90 Days: A Review
Reviews on Recent Clinical Trials Linezolid Activity Against Disseminated Listeria monocytogenes Meningitis and Central Nervous System Abscesses: Focus on Early Drug Myelotoxicity
Current Drug Safety Novel Therapeutic Agents for Resistant Gram-Positive Infections
Current Drug Therapy Serum Tryptophan, Tryptophan Catabolites and Brain-derived Neurotrophic Factor in Subgroups of Youngsters with Autism Spectrum Disorders
CNS & Neurological Disorders - Drug Targets Current Concepts in SLE Thrombocytopenia: From Pathophysiology to Therapeutic Interventions
Current Rheumatology Reviews Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design DNA Methylation in the Pathogenesis of Systemic Lupus Erythematosus
Current Pharmacogenomics Clinical and Electroencephalographic Assessment of Cefepime During Treatment of Nosocomial Infections in Neurological Patients
Central Nervous System Agents in Medicinal Chemistry Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research Antifungal Azole Derivatives and their Pharmacological Potential: Prospects & Retrospects
The Natural Products Journal Amphotericin B-Loaded Poly(Lactide)-Poly(Ethylene Glycol)-Blend Nanoparticles: Characterization and In Vitro Efficacy and Toxicity
Current Nanoscience Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Current Cancer Drug Targets